PRJNA549693
Massively parallel CRISPR-Cas binding assays
Most CRISPR-Cas systems suffer from off-target effects and unpredictable non-specific binding that negatively impact their reliability and broader applicability. To better evaluate the impact of mismatches on DNA target recognition and binding affinities, we develop a massively parallel CRISPR interference (CRISPRi) assay called Xseq to measure the affinity between tens of thousands of CRISPR RNA (crRNA) and target DNA sequences.